Masatoshi Kudo suggested that continuous normalization of three tumor markers (AFP, AFP-L3, and PIVKA-II) for 12 to 24 weeks could serve as a criterion for discontinuing treatment in liver cancer patients with complete responses (7). This evidence concerns the gene AFP and liver cancer.